Nonimmune Hemolysis in Myelodysplastic Syndromes

Patients with MDS and nonimmune hemolysis were more likely to have EZH2 and U2AF1 mutations.

Anemia is identified in most patients with myelodysplastic syndromes (MDS), often due to ineffective red cell production. Rarely, patients with MDS have increased red cell destruction, owing to hemolysis. From a mechanistic standpoint, autoimmune hemolysis is rarely identified, as is an acquired hemoglobinopathy (acquired alpha thalassemia). To better characterize prevalence and clinical and molecular associations among MDS patient with hemolysis, investigators conducted a retrospective single-center analysis of 519 patients with MDS and measured haptoglobin. The 54 patients (10%) with haptoglobin <10 mg/dL were defined as having hemolysis. Only 13% of patients with low haptoglobin had a positive Coombs test.

Patients with MDS-hemolysis, com…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Nonimmune Hemolysis in Myelodysplastic Syndromes

Topics

Reviewing Author